MENU
IBRN
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for IBRN with price predictions
Nov 11, 2026

Momentum Indicator for IBRN turns positive, indicating new upward trend

IBRN saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned positive. In 67 of the 74 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBRN's RSI Indicator exited the oversold zone, 11 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.

The Moving Average Convergence Divergence (MACD) for IBRN just turned positive on October 20, 2026. Looking at past instances where IBRN's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.

IBRN moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +6.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRN advanced for three days, in 175 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 174 of 197 cases where IBRN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for IBRN moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

IBRN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF (IBRN) ETF is 4.24B. The market cap for tickers in the group ranges from 16.16M to 58.01B. ARGX holds the highest valuation in this group at 58.01B. The lowest valued company is ABOS at 16.16M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF (IBRN) ETF was 115%. For the same ETF, the average monthly price growth was 99%, and the average quarterly price growth was 221%. PEPG experienced the highest price growth at 115%, while ABEO experienced the biggest fall at -45%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF (IBRN) ETF was 0%. For the same stocks of the ETF, the average monthly volume growth was 61% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 38
Price Growth Rating: 60
SMR Rating: 90
Profit Risk Rating: 85
Seasonality Score: 8 (-100 ... +100)
Momentum Indicator for IBRN turns positive, indicating new upward trend